Status:
UNKNOWN
The Monitor of Serum Prolactin Level in a 3 Months Aripiprazole Trial
Lead Sponsor:
Yu-Li Hospital
Conditions:
Schizophrenia, Tardive Dyskinesia, Metabolic Syndrome
Eligibility:
All Genders
16-65 years
Phase:
PHASE4
Brief Summary
A short term post-market monitoring of serum prolactin level change among patients with schizophrenia shifting from other antispychotics to different dosages of aripiprazole.
Detailed Description
This is an open-label clinical trial of adult inpatients or outpatients with a diagnosis of schizophrenia, schizoaffective disorder, or schizophreniform disorder as measured by the Diagnostic and Stat...
Eligibility Criteria
Inclusion
- Patients may be included in the study if they meet the following criteria:
- Males and females 16-65 years of age
- Diagnosis of schizophrenia, schizoaffective or schizophreniform disorder
- Each individual must have a level of understanding sufficient to perform all tests and examinations required
- Individuals must be willing to fast after midnight the evening prior to study visit
- Individuals must be willing to provide a small sample of blood for evaluation
- Individuals must be willing to participate in a short 30-45 minute clinical interview
Exclusion
- Patients may be excluded from the study for any of the following reasons:
- A current diagnosis of diabetes mellitus
- Serious unstable illness such that death is anticipated within 1 year or intensive care unit hospitalization for the condition is anticipated within 6 months
- Uncorrected hypothyroidism or hyperthyroidism
- Uncorrected tumor secreting ectopic prolactinemia
Key Trial Info
Start Date :
May 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 1 2007
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT00468533
Start Date
May 1 2006
End Date
July 1 2007
Last Update
May 2 2007
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Yu-Li Hospital, DOH
Hualien City, Hualien, Taiwan, 981